Marinus Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 05/05/2024
Marinus Pharmaceuticals Stock Forecast and Price Target
The average price target of $6.00 for Marinus Pharmaceuticals's stock set by distinguished analysts in recent weeks would represent a potential upside of approximately 297.35% from the last closing price in May, 2024 if reached by the end of the year. This potential increase is based on a high estimate of $27.00 and a low estimate of $2.00. If you're considering investing in MRNS stock, it's important to look at its competitors too.
297.35% Upside
Marinus Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Marinus Pharmaceuticals's Price has increased by 100.00%, going from $0.00 to $0.00. In the next year, analysts are expecting an increase in Fair Value, predicting it will reach $1.62 – an increase of 100.00%. The Marinus Pharmaceuticals forecast is for Fair Value to reach $3.06 or grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$163.79 | Buy/Sell | $178.42 | 12.95% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$311.29 | Buy/Sell | $303.65 | 2.80% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$64.78 | Buy/Sell | $87.82 | 23.49% |
| ALXN Stock Forecast | Alexion Pharmaceuticals | - |
0
|
$182.50 | Buy/Sell | $177.38 | -100.00% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$217.51 | Buy/Sell | $299.62 | 32.64% |
Marinus Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Marinus Pharmaceuticals's Revenue has increased by 1701.74%, going from $1.72M to $30.99M. In the next year, analysts are expecting an increase in Revenue, predicting it will reach $42.18M – an increase of 36.11%. The Marinus Pharmaceuticals forecast is for Revenue to reach $585.97M or grow by 1790.84%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$82.44 | Buy/Sell | $111.56 | 33.43% |
| INCY Stock Forecast | Incyte | Outperform |
9
|
$53.76 | Buy/Sell | $77.05 | 46.02% |
| VKTX Stock Forecast | Viking Therapeutics | Buy |
5
|
$76.97 | Buy/Sell | $34.00 | 49.41% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BPMC Stock Forecast | Blueprint Medicines | Outperform |
6
|
$107.19 | Buy/Sell | $85.71 | 11.48% |
| ARNA Stock Forecast | Arena Pharmaceuticals | - |
6
|
$99.99 | Buy/Sell | $100.00 | -100.00% |
| CCXI Stock Forecast | ChemoCentryx | - |
8
|
$51.99 | Buy/Sell | $52.00 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CBAY Stock Forecast | CymaBay Therapeutics | - |
8
|
$32.44 | Buy/Sell | $27.73 | -100.00% |
| IOVA Stock Forecast | Iovance Biotherapeutics | Buy |
4
|
$13.63 | Buy/Sell | $20.42 | 87.09% |
| ARWR Stock Forecast | Arrowhead Pharmaceuticals | Outperform |
7
|
$24.44 | Buy/Sell | $52.00 | 125.04% |
Marinus Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Marinus Pharmaceuticals's EBITDA has grown, increasing from $-67.60M to $-126.13M – a growth of 86.58%. For the following year, the 0 analysts predict that Marinus Pharmaceuticals's EBITDA will drop by 18.44%, reaching $-102.87M. In 2030, the professionals' prediction is that MRNS's EBITDA will decrease by 15.60%, reaching $-106.45M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DRNA Stock Forecast | Dicerna Pharmaceuticals | - |
7
|
$38.01 | Buy/Sell | $35.06 | -100.00% |
| FOLD Stock Forecast | Amicus Therapeutics | Outperform |
7
|
$10.40 | Buy/Sell | $17.90 | 92.31% |
| ACAD Stock Forecast | ACADIA Pharmaceuticals | Outperform |
6
|
$17.05 | Buy/Sell | $33.78 | 75.95% |
Marinus Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Marinus Pharmaceuticals's EBIT has grown by 93.54%, from $-67.94M to $-131.49M. For the next year, analysts are expecting EBIT to reach $-132.22M – an increase of 0.56%. According to professionals, by 2030, Marinus Pharmaceuticals's EBIT will have decreased by 621.20%, falling down to $685.32M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CLDX Stock Forecast | Celldex Therapeutics | Buy |
11
|
$42.56 | Buy/Sell | $63.29 | 80.92% |
| VCEL Stock Forecast | Vericel | Buy |
8
|
$47.83 | Buy/Sell | $42.58 | 14.99% |
| ARDX Stock Forecast | Ardelyx | Buy |
11
|
$8.72 | Buy/Sell | $9.94 | 60.55% |
Marinus Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Marinus Pharmaceuticals's EPS has increased by 100.00%, going from $-2.80 to $0.00. In the next year, analysts are expecting an increase in EPS, predicting it will reach $-2.28 – an increase of 100.00%. The Marinus Pharmaceuticals forecast is for EPS to reach $10.40 or grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AGIO Stock Forecast | Agios Pharmaceuticals | Outperform |
9
|
$34.54 | Buy/Sell | $40.00 | 28.84% |
| DVAX Stock Forecast | Dynavax Technologies | Outperform |
11
|
$11.74 | Buy/Sell | $25.00 | 108.69% |
| ADMA Stock Forecast | ADMA Biologics | Buy |
9
|
$6.81 | Buy/Sell | $6.00 | 17.47% |
Site Navigation
.jpg)